Cytos faces job cuts after blood pressure vaccine failure
Shares in Cytos Biotechnology have collapsed after the Swiss firm said that a trial of its hypertension vaccine has failed, forcing the company to make major job cuts.
Read MoreAuthor: Kevin Grogan
Jordan’s Hikma looks to partner with big pharma
Jordanian generics drugmaker Hikma Pharmaceuticals has posted a decline in operating profits for 2008, due to a poor showing in the USA, but a healthy revenue rise.
Read MoreFDA staff fears over bleeding risk of Bayer/J&J’s rivaroxaban
The chances of Bayer and Johnson & Johnson getting approval for their oral anticoagulant Xarelto look grimmer today after US regulatory staff declared their doubts about the safety of the drug.
Read MorePfizer raises $13.5 billion in debt offering
Pfizer has followed in the footsteps of Roche and has placed an unspecified number of bonds to raise around $13.5 billion in a debt offering that will help finance its $68 billion acquisition of Wyeth.
Read MoreSchering-Plough withdraws Cylatron melanoma filing in EU
The European Medicines Agency says that it has been formally notified by Schering-Plough that the company is withdrawing a submission to get the green light for Cylatron for melanoma.
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
